Health TrialsbyHealthPanel

Hematological Markers MPV, PLR, and NLR in Primary Versus Secondary Antiphospholipid Syndrome

ConditionAntiphospholipid Syndrome
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorNew Valley University

About this trial

Antiphospholipid syndrome is a thrombo-inflammatory autoimmune disorder with a complex antiphospholipid antibody-mediated pathogenesis, and high heterogeneity in clinical presentation and disease course. Clinical presentation in antiphospholipid syndrome includes venous and arterial thrombosis, pregnancy complications, and a broad range of microvascular and non-thrombotic manifestations

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Adults (age ≥18 years)

Diagnosis of APS based on updated Sydney classification criteria confirmed by: Clinical history of thrombosis and/or pregnancy morbidity, Persistent presence (≥12 weeks) of antiphospholipid antibodies (aCL, anti-β2-glycoprotein I, and/or lupus anticoagulant)

Disqualifiers

Current infection or inflammatory condition unrelated to APS

Hematological malignancies or other blood disorders

Recent blood transfusion or platelet-altering medications other than APS treatments

Trial population

Patients will be categorized as: Primary APS: APS without other systemic autoimmune diseases Secondary APS: APS associated with autoimmune diseases such as systemic lupus erythematosus (SLE)

Trial design

Design model

Other

Time perspective

Retrospective

Treatments tested in this trial

  • • Complete blood count , MPV

    Diagnostic test

    CBC report

  • Calculation of PLR: Platelet count / Lymphocyte count and Calculation of NLR:

    Diagnostic test

    CBC report

  • Antiphospholipid antibody profile

    Diagnostic test

    Patient record

Treatment groups

150 Participants
are divided into 2 treatment groups
Group A: 13 interventions
Group B: 23 interventions

Trial outcomes

Primary outcomes

1

Measurement of Mean platelet Volume in patients diagnosed with primary APS

Time frame
Baseline
2

Measurement of Mean platelet Volume in patients diagnosed with secondary APS

Time frame
Baseline

Secondary outcomes

1

Measurement of Platelet - lymphocyte ratio in patients diagnosed with primary APS and those with secondary APS

Time frame
"Baseline"
2

Measurement of Neutrophil - lymphocyte ratio in patients diagnosed with primary APS and those with secondary APS

Time frame
"Baseline"

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

New Valley University

Lead sponsor

Source ClinicalTrials.gov
Apply now